Find Faculty Members at MUSC.

Angela Yoon

Angela J. Yoon

Provider Image
  • Professor
  • College of Dental Medicine
  • Department of Biomedical & Community Health Sciences
Academic Focus
  • Oral & Maxillofacial Pathology
  • Oral Cancer
  • Oral Mucosal Lesions
Faculty email addresses should not be used to seek medical advice or to make medical appointments. Please visit MyChart for medical appointments or to contact your provider.


Office Location


  • Professor and Director, Oral and Maxillofacial Pathology, Department of Biomedical & Community Health Sciences (College of Dental Medicine), and Department of Otolaryngology - Head and Neck Surgery (College of Medicine), College of Graduate Studies, Medical University of South Carolina3/2022-Present
  • Director, Biorepository & Tissue Analysis Shared Resources, Hollings Cancer Center, MUSC; 12/2023-Present
  • John W. Richter Associate Professor and Director, Division of Oral and Maxillofacial Pathology (College of Dental Medicine), and Department of Pathology and Cell Biology (College of Medicine), Columbia University Irving Medical Center, NY; 7/2013-2/2022
  • John W. Richter Assistant Professor, Division of Oral and Maxillofacial Pathology (College of Dental Medicine), Columbia University Irving Medical Center, NY; 7/2006-2/2013



  • Diplomate (2006): American Board of Oral & Maxillofacial Pathology
  •  Residency (2006): NY Presbyterian Hospital/Columbia University Medical Center, NY
  • DDS (2003): Columbia University, School of Dental and Oral Surgery, NY 
  • MPH (1999): Boston University, School of Public Health, MA
  • MAMSc (1999): Boston University, School of Medicine, MA
  • BA (1996): Boston University, College of Liberal Arts & Sciences, MA


Patient Care:

Dr. Angela Yoon is an Oral & Maxillofacial Pathologist with expertise in the clinical management of patients with a variety of mucosal conditions and is adept at conducting proper head and neck examinations, performing mucosal biopsies, and providing proper treatments. Dr. Yoon's faculty practice can be found here.  

Angela Jiyeon Yoon, DDS, MPH, MAMSc - Cancer - Head & Neck Tumors in Charleston, SC | MUSC Health


Biopsy Service:

Dr. Yoon is also a director of the Oral & Maxillofacial Pathology Biopsy service. She has extensive experience in the field and provide comprehensive diagnostic microscopic interpretations and consultations.


Clinical Trial & Research:

As an academic Oral & Maxillofacial Pathology clinician-scientist, Dr. Yoon is engaged in the translation of laboratory science into new molecular risk assessment strategies, and also in improving therapies for oral epithelial neoplasms. She has background in public health, dentistry, and oral medicine, and have dedicated a considerable part of her career to the diagnosis and management of oral precancers and cancers. Devoted to improving clinical management, Dr. Yoon has conducted a number of studies assessing the molecular diagnostic and prognostic biomarkers of oral neoplasm. Dr. Yoon is investigating the prognostic utility of microRNA-based markers for oral cancer patientsShe also is currently leading a clinical trial evaluating the efficacy of immunomodulatory agent for oral cancer used in neoadjuvant setting.

Topical Aldara (Imiquimod) for Oral Cancer - Full Text View -

The clinical trial patients are being cared for in conjunction with the Department of Otolaryngology - Head and Neck Surgery.

Angela Jiyeon Yoon, DDS, MPH, MAMSc - Cancer - Head & Neck Tumors in Charleston, SC | MUSC Health

NIH/NCI R21 CA252441 (PI:Yoon) 4/01/2021-3/31/2023; ‘Exploratory clinical trial of topical Imiquimod 5% cream as window-of-opportunity monotherapy for early-stage oral cancer’.  The aim of the study is to assess if Imiquimod 5% topical cream administered prior to surgery will cause necrosis and apoptosis of tumor cells and trigger an antitumor immune response that inhibits tumor growth in early-stage oral cancer patients, improving overall survival.

NIH/NIDCR R01 DE026801 (PI: Yoon) 7/01/2017-6/30/2021; ‘MicroRNA-based prognostic model for early stage oral cancer patients’. The aim of the study is to develop a clinically applicable microRNA (miRNA)-based prognostic modality that can reliably assess cancer-specific mortality risk and provide guidance in selecting risk-adjusted therapy for patients with early-stage (TNM Stages I/II) oral squamous cell carcinoma (OSCC).